FDA has released guidance to holders of BLAs regarding the types of post-approval changes to an approved BLA that can be documented in an annual report. Cited are changes in the product, production process, quality controls, equipment, facilities, or responsible personnel that have a “minimal potential” to have an adverse effect on product quality.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
